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Abstract
Purpose Economic evaluations of mental health interventions often measure health beneit in terms of utility values derived 
from the EQ-5D. For the ive-level version of the EQ-5D, there are two methods of estimating utility [crosswalk and stated 
preference (5L-SP)]. This paper explores potential impacts for researchers and decision-makers when comparing utility 
values derived from either method in the speciic context of mental health.
Methods Baseline EQ-5D-5L data from three large randomised controlled trials of interventions for mental health conditions 
were analysed. Utility values were generated using each method. Mean utility values were compared using a series of t tests 
on pooled data and subgroups. Scenario analyses explored potential impacts on cost-efectiveness decisions.
Results EQ-5D data were available for 1399 participants. The mean utility value for each trial was approximately 0.08 higher 
when estimated using the 5L-SP approach compared to crosswalk (p < 0.0001). The diference was greatest among people 
reporting extreme anxiety/depression (mean utility 5L-SP 0.309, crosswalk 0.084; diference = 0.225; p < 0.0001). Identical 
improvements in health status were associated with higher costs to gain one QALY with the 5L-SP approach; this is more 
pronounced when improvements are across all domains compared to improvements on the anxiety/depression domain only.
Conclusions The two approaches produce signiicantly diferent utility values in people with mental health conditions. 
Resulting diferences in cost per QALY estimates suggest that thresholds of cost-efectiveness may also need to be reviewed. 
Researchers and decision-makers should exercise caution when comparing or synthesising data from trials of mental health 
interventions using diferent utility estimation approaches.
Keywords Health-related quality of life · Mental health · Schizophrenia · Depression · Utility · EuroQol
Introduction
In the UK, approximately one in four adults experience men-
tal health problems in a given year [1]. The annual cost to 
society is estimated to be £70–100 bn (20% from health and 
social care costs, 30% from lost productivity, and 50% from 
human sufering) [2]. Mental illness is the largest category 
of NHS disease expenditure and accounts for 28% of the 
total burden of disease in the UK [2].
Mental health disorders have a negative impact on health-
related quality of life (HRQoL) which varies according to 
the speciic diagnosis [3, 4]. There are many ways in which 
mental health problems can impact HRQoL, for instance 
feelings of hopelessness or anxiety, low self-esteem, a lack 
of conidence, loneliness, and feeling a lack of control [5].
The EuroQol 5 dimension questionnaire (EQ-5D) is 
a short, self-report measure used to assess health status 
over ive domains: mobility, self-care, ability to do usual 
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activities, pain/discomfort, and anxiety/depression [6, 7]. 
The EQ-5D-3L asks respondents to rate their health at one 
of three levels (see Box 1) for each of the health domains. 
This produces 243 possible proiles of health. In the 1990s, 
a series of time-trade-of (TTO) exercises were conducted 
to generate a country-speciic health state index value for 
each of the health proiles (e.g. [8] in the UK). These values 
correspond to how favourable or unfavourable each health 
state is viewed by the general population of a particular 
country. They are used in economic evaluations of health-
care interventions to quantify health utility and combined 
with life expectancy to calculate quality-adjusted life-years 
(QALYs) for cost–utility analyses, as recommended by the 
National Institute for Health and Care Excellence (NICE) 
in England [9].
There has been some debate over whether utility values 
derived from the EQ-5D-3L are sensitive to important clini-
cal health improvements for people with mental health con-
ditions as only one health domain directly measures mental 
health [10, 11]. A 5-level version of the EQ-5D has now 
been published which aims to improve on the 3-level design, 
making it more sensitive to smaller changes in health. In 
the 5L version, there are ive possible responses along the 
same best-to-worst scale as the 3-level version (see Box 1), 
producing 3125 possible proiles of health [7].
When the EQ-5D-5L was irst released, a probability-
based, non-parametric, mapping exercise was conducted to 
produce a set of utility values from the 3L value set (i.e. 
restricted to the same range) [12]. This is referred to as the 
crosswalk approach. In 2017, the results were published 
from an exercise combining two stated preference (SP) 
methods, TTO and discrete choice experiment (DCE) [13], 
to derive an EQ-5D-5L utility value set for England [14]. 
This will subsequently be referred to as the 5L-SP approach.
It is known that comparable improvements in health sta-
tus are measured as larger gains in health utility with the 
3L than the 5L version [15]. This is the combined efect 
of the diferent number of levels, valuation protocol, and 
range/distribution of possible utility values. The valuation 
protocol and range/distribution of utility values are poten-
tial mechanisms for how diferences may arise between EQ-
5D-5L utility values estimated using the 5L-SP and cross-
walk approaches [16].
These differences may have specific implications for 
people with mental health conditions. For the crosswalk 
utility values, anxiety/depression is the third most impor-
tant domain (size of the level 5 coeicient), whereas for the 
5L-SP values anxiety/depression is the second most impor-
tant domain [14]. Furthermore, the TTO exercise for Eng-
land found that people did not diferentiate between severe 
(level 4) and extreme (level 5) anxiety/depression as had 
been expected [13]. This was somewhat corrected for by 
the hybrid TTO and DCE approach. However, an improve-
ment in anxiety/depression from ‘extreme’ to ‘severe’, which 
may represent an important improvement for an individual 
experiencing these health states, is still associated with a 
smaller QALY gain than other one-level improvements on 
this domain.
There may be important implications of these difer-
ences when comparing findings from studies of mental 
health interventions which have used diferent versions and 
approaches for estimating utility. An important strength of 
the crosswalk approach for the 5L version is that because 
utility values directly map onto those generated from the 3L 
version, in theory results can be compared between studies 
using the diferent versions. Whereas the diferences in the 
methods used mean, it is not appropriate to use 5L-SP and 
3L-TTO utility values interchangeably [15].
Methods
The aim of this analysis is to calculate utility values derived 
from the EQ-5D-5L using each of the two approaches to 
explore potential implications for researchers and decision-
makers. Mental health may be considered a special case in 
relation to the EQ-5D and so this aim was addressed in the 
context of three large randomised controlled trials (RCTs) 
of interventions for mental health conditions.
Our key research questions are as follows:
1. How do utility values difer between the two methods 
(5L-SP and crosswalk) used to estimate utility from the 
EQ-5D-5L?
2. How do EQ-5D-5L responses and utility values difer 
across three study samples with diferent mental health 
conditions?
3. What impact does the method of utility estimation have 
on estimates of cost-efectiveness?
The studies were selected from existing datasets held by 
the authors for trials which collected baseline EQ-5D-5L and 
were available at the time of the analysis. Protocols for the 
respective studies describe the methods completely [17–19].
The key details are as follows:
Box 1  Responses on the EQ-5D three- and ive-level versions
Three-level Five-level
No problems No problems
Slight problems
Some problems Moderate problems
Severe problems
Extreme problems Extreme problems
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• COINCIDE—COlaborative INterventions for CIrcula-
tion and DEpression [17]
– Population—Adults with diabetes and/or coronary 
heart disease with comorbid depression
– Sample—n = 387, 38% female, mean age 59 years.
• EQUIP—Enhancing the Quality of User Involved care 
Planning in mental health services [18]
– Population—A mixed population of adults with a 
severe mental illness (including diagnoses of schizo-
phrenia, bipolar disorder, and depression) accessing 
secondary care mental health services.
– Sample—n = 602, 60% female, mean age 55 years.
• FOCUS—Focusing On Clozapine Unresponsive Symp-
toms [19]
– Population—People aged at least 16  years with 
conirmed treatment-resistant schizophrenia that is 
poorly responsive to an adequate trial of clozapine 
monotherapy
– Sample—n = 487, 28% female, mean age 43 years.
This analysis was restricted to baseline EQ-5D-5L data 
as follow-up data were not available for all three studies at 
the time of the analysis. Utility values were calculated from 
the EQ-5D-5L using the crosswalk approach [12] and the 
5L-SP approach [14].
Unless stated otherwise, the analyses were conducted on 
data from all three studies simultaneously (pooled data). 
This means that the proportionate diferences between utility 
values calculated using the two approaches were explored in 
the largest dataset possible, irrespective of diferences in the 
characteristics of the diferent trial samples. The responses 
for the EQ-5D-5L were summarised graphically using the 
eq5dds command in STATA [20].
Descriptive statistics [mean, standard deviation (SD), 
range, 95% conidence interval (CI)] were used to sum-
marise the utility values estimated by each approach. The 
rationale for adjusting for confounders in statistical analyses 
is that confounders have an efect on both the independent 
(input) and dependent (outcome) variables in a relationship. 
For the analyses reported here, there are no input variables, 
and only an outcome variable (utility) was calculated in two 
diferent ways. As such, the statistical approach involved 
direct comparison of unadjusted mean values. T tests were 
used to evaluate whether diferences in the mean utility val-
ues produced by the alternative approaches were signiicant.
Subgroup analysis
To further explore the ‘mental health’ domain of the EQ-
5D-5L, subgroups were deined according to the level of 
anxiety/depression. Mean utility values were compared 
across the subgroups.
Scenario analysis
To explore the possible implications of the diferent utility 
estimation methods on cost-efectiveness estimates, pseudo 
follow-up EQ-5D-5L proiles were generated for all partici-
pants from their baseline values. This was done for two dif-
ferent scenarios of health status improvement (scenario 1: 
1-level improvement on the anxiety/depression domain; sce-
nario 2: 1-level improvement on all domains). For example, 
a participant with a baseline proile of 12,345 would have 
a ‘follow-up’ proile of 12,344 in scenario 1 and 11,234 in 
scenario 2. As with real-world follow-up data, under both 
scenarios it was not possible to ‘improve’ beyond level 1 on 
any domain. This ensured that the pseudo follow-up proiles 
related directly to the utility value sets for both the cross-
walk and SP approaches. ‘Follow-up’ utility values were 
then calculated, in the same way as baseline values, using 
each estimation method. QALY gains were then estimated 
for each individual by subtracting their baseline utility value 
from their follow-up value, assuming a 1-year time hori-
zon. The mean QALY gain across the whole sample (pooled 
dataset) was used to calculate incremental cost-efectiveness 
ratios (ICERs) for each scenario over a range of costs (£500, 
£1000, £5000, and £10,000).
All analyses were conducted on a complete case basis 
using the STATA software program (StataCorp. 2013. Stata 
Statistical Software: Release 13. College Station, TX: Stata-
Corp LP).
Results
The characteristics of the pooled sample are reported in 
Table 1. The pooled sample had a mean age of 48 years, 
just over half were male, and the majority were of white 
ethnicity. The most common level of education within the 
sample was compulsory secondary education (approximately 
age 16). Approximately one-ifth of the sample were in paid 
employment (full or part time). The total sample size was 
1476, 1399 (95%) of whom had completed the EQ-5D-5L.
Figure 1 shows the distribution of EQ-5D-5L responses 
for each domain (pooled data). Whilst the most common 
response on the irst four domains is ‘no problems’, the 
720 Quality of Life Research (2018) 27:717–724
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anxiety and depression domain peaks at ‘moderate prob-
lems’ and shows less variation across the ive levels.
Table 2 and Fig. 2 show the calculated EQ-5D-5L utility 
values using both methods. For both the pooled data and 
each trial separately, the diference in the mean utility value 
derived using the 5L-SP approach was approximately 0.08 
higher than the crosswalk value, a statistically signiicant 
diference (p < 0.05).
Participants in the COINCIDE trial (depression alongside 
a long-term physical condition) had the lowest mean utility 
values; this group also had the oldest average age. The high-
est mean utility value came from the FOCUS trial (schizo-
phrenia). Both the EQUIP and FOCUS trials included partic-
ipants with serious mental illness (schizophrenia is included 
in this broader umbrella term) which means that they could 
plausibly be used to inform parameters in the same eco-
nomic model. When the same utility estimation method is 
used, the mean baseline utility is higher for the FOCUS trial 
than for EQUIP by between 0.044 (crosswalk) and 0.0447 
(5L-SP). However, if baseline utility was reported using 
the 5L-SP values for FOCUS and the crosswalk values for 
EQUIP, the FOCUS utility values would be higher by 0.127 
(i.e. 0.714 − 0.587 = 0.127), and if the other utility value was 
used in each case, the EQUIP utility values would be higher 
by 0.036 (i.e. 0.667 − 0.631 = 0.036).
Table 3 shows the mean utility values derived using each 
approach for subgroups of the pooled dataset deined by par-
ticipants’ response on the anxiety/depression domain of the 
EQ-5D-5L. By far, the greatest diference in utility values 
calculated using the diferent methods is seen in those who 
reported being extremely anxious or depressed, 8% of the 
pooled dataset.
Table 1  Baseline characteristics of the pooled sample from the three 
trials
*Data available for FOCUS and EQUIP trials only (n = 1089)
**Data available for COINCIDE and EQUIP trials only (n = 989)
n = 1476 Mean (SD) or n/N (%)
Age (years) 48 (13.2); n = 1462
Sex (female) 640/1461 (44%)
Ethnicity (white) 1244/1472 (85%)
Education*
 Secondary school 453/1023 (44%)
 Further education 274/1023 (27%)
 Higher education 296/1023 (29%)
Employment status (in paid employment)** 178/963 (18%)
Fig. 1  Distribution of responses on EQ-5D-5L questionnaire (pooled data)
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Table  4 reports ICERs for a hypothetical interven-
tion associated with either a 1-level improvement from 
baseline in anxiety/depression or a 1-level improvement 
from baseline on all EQ-5D-5L domains. In both of these 
instances, the 5L-SP approach estimates a higher cost to 
gain one QALY than the crosswalk approach. This relects 
how an identical change in health status is associated with a 
smaller improvement in utility value according to the 5L-SP 
approach rather than the crosswalk approach.
If a decision-maker used a cost-efectiveness threshold 
of £17,000 per QALY gained, then the intervention improv-
ing anxiety/depression by one level, at a net cost of £1000, 
would only be considered cost-efective according to the 
crosswalk approach (Table 4).
A 1-year time horizon has been assumed for these analy-
ses; however, there would be a multiplicative efect over 
time (i.e. a utility value of 0.08 would equate to 0.08 QALYs 
over 1 year, 0.16 QALYs over 2 years, and 0.80 QALYs over 
10 years).
Discussion
This analysis provides EQ-5D-5L scores and utility values 
for three large mental health trials. The utility values esti-
mated according to the two approaches were signiicantly 
diferent from each other. The 5L-SP approach estimated 
utility values approximately 0.08 higher than the crosswalk 
approach for the same health proiles.
Another comparison of utility values estimated using the 
two approaches, albeit for a range of diferent health condi-
tions, reported a similar mean diference in utility of around 
0.09 [16]. Our indings also support previous analyses which 
demonstrated how comparable improvements in health are 
measured as larger using the 3L (i.e. the same value set at 
the crosswalk approach) and 5L versions of the EQ-5D [15].
In the analysis reported here, the diference between 
5L-SP and crosswalk utility values was around three times 
the size among participants reporting level 5 anxiety/depres-
sion than for those reporting any other level. This corre-
sponds to the inding reported by the authors who derived 
Table 2  Summary statistics for utility values estimated using the 
alternative approaches
EQ-5D-5L utility Mean (SD) Min Max 95% CI
Pooled data (n = 1399)
 5L-SP 0.644 (0.28) − 0.263 1 0.629–0.659
Crosswalk 0.565 (0.31) − 0.555 1 0.549–0.581
  Mean diference (p 
value)
0.079 (p < 0.0001)
COINCIDE (n = 366)
 5L-SP 0.521 (0.29) − 0.218 1 0.491–0.551
 Crosswalk 0.449 (0.29) − 0.367 1 0.419–0.479
  Mean diference (p 
value)
0.072 (p < 0.0001)
EQUIP (n = 580)
 5L-SP 0.667 (0.30) − 0.263 1 0.643–0.692
 Crosswalk 0.587 (0.34) − 0.555 1 0.559–0.614
Mean diference (p 
value)
0.081 (p < 0.0001)
FOCUS (n = 453)
 5L-SP 0.714 (0.22) − 0.127 1 0.694–0.734
 Crosswalk 0.631 (0.26) − 0.453 1 0.608–0.655
  Mean diference (p 
value)
0.082 (p < 0.0001)
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Fig. 2  Utility values for the original study samples, by utility estima-
tion approach
Table 3  Mean utility values 
(pooled data) by response on 
anxiety/depression domain of 
EQ-5D-5L and utility values 
from published tarifs for 
diferent health proiles
n/N (%) 5L-SP Crosswalk Diference (5L-
SP–crosswalk)
p value for 
diference
Not anxious or depressed
[253/1399 (18%)]
0.885 0.829 0.057 < 0.0001
Slightly anxious or depressed
[320/1399 (23%)]
0.740 0.669 0.070 < 0.0001
Moderately anxious or depressed [507/1399 (36%)] 0.642 0.574 0.069 < 0.0001
Severely anxious or depressed
[203/1399 (15%)]
0.388 0.325 0.063 < 0.0001
Extremely anxious or depressed [116/1399 (8%)] 0.309 0.084 0.225 < 0.0001
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the TTO utility tarifs for the EQ-5D-5L that people did not 
diferentiate between level 4 and level 5 anxiety/depression 
as had been expected during the TTO exercise [13].
Comparing the diferent trials included in this analysis 
showed that as long as the same utility estimation method is 
used for both samples, similar diferences between the mean 
utility values for FOCUS and EQUIP are found (FOCUS had 
higher utility with both methods—0.044 (crosswalk) and 
0.047 (5L-SP)). However, comparing the values generated 
by the diferent utility estimation methods demonstrated how 
conlicting results could occur. For example, EQUIP utility 
values were higher than the FOCUS values when the 5L-SP 
approach was used for EQUIP and the crosswalk approach 
for FOCUS.
Scenario analyses conirmed that an intervention may 
be less likely to be classiied as cost-efective (same health 
improvement associated with a lower QALY gain and thus 
a higher ICER) using the 5L-SP method compared with the 
crosswalk method.
Strengths and weaknesses
A key strength of this analysis is the high quality of the data 
sources. The data come from three large, robust trials of dif-
ferent mental health conditions. The level of missing data 
is minimal with 95% of participants recruited to the trials 
completing the EQ-5D at baseline.
One limitation of this analysis is that the TTO value set 
for the EQ-5D-5L was from a sample of the population liv-
ing in England and thus the research is speciic to England 
and indings may not be generalisable to other countries. 
Furthermore, the indings may not be relevant to mental 
health conditions that were not included here.
Another limitation that can be addressed in future work 
is that this analysis included only baseline data from the 
studies and so it was not possible to explore diferences in 
ICERs. It will be interesting to examine this when follow-up 
data are available.
Potential implications
There are two key areas for which these indings may have 
potentially important implications: decision-making and evi-
dence synthesis. In terms of decision-making, the method 
of utility estimation could determine whether an ICER falls 
above or below a particular cost-efectiveness threshold. 
Assuming that the same threshold for cost-efectiveness is 
applied, it is possible that interventions may be considered 
cost-efective using the crosswalk method but may not using 
the 5L-SP method. Results from this analysis suggest that 
the impact of this is likely to be greatest for samples with 
a large proportion of people reporting extreme anxiety/
depression.
Evidence synthesis involves bringing together estimates 
of costs, beneits (QALYs), and/or ICERs from a range of 
sources (e.g. systematic reviews, meta-analyses). EQ-5D-5L 
data calculated using the crosswalk method are at present 
most likely to be identiied by systematic reviews, as these 
have been available for longer. Evidence synthesis is also 
often part of the economic decision modelling process. As 
shown here using the cautionary example of the EQUIP and 
FOCUS studies, which, because of the overlapping mental 
health conditions they include, could potentially be included 
in the same decision model, it is important that researchers 
are aware that combining utility values estimated using dif-
ferent approaches is not necessarily straightforward. Eco-
nomic models are also used to extrapolate indings from 
RCTs over longer periods, and there may also be speciic 
implications of utility estimation method in these models as 
diferences are multiplied over time.
A recommendation for future economic evaluations using 
the EQ-5D-5L would be to ensure that results according to 
both methods of utility estimation are reported, or at least 
that the method of utility estimation is clearly reported in 
publications of the results.
This analysis will be of particular interest to decision-
making bodies, such as the National Institute for Health 
Table 4  ICERs calculated 
at diferent levels of net cost 
for two scenarios of health 
improvement applied to the 
pooled dataset; values are cost 
to gain one QALY (assuming 
utility values are accrued over 
1 year)
a Mean QALY gain in sample (pooled data): 5L-SP 0.054; crosswalk 0.061; diference 0.007
b Mean QALY gain in sample (pooled data): 5L-SP 0.182; crosswalk 0.206; diference 0.024
Health status improvement Cost ICER (£/QALY gained) Diference
5L-SP Crosswalk
1-level improvement in anxiety/  depressiona £500 £9259 £8197 £1062
£1000 £18,519 £16,393 £2126
£5000 £92,593 £81,967 £10,626
£10,000 £185,185 £163,934 £21,251
1-level improvement on each EQ-5D  domainb £500 £2747 £2427 £320
£1000 £5495 £4854 £641
£5000 £27,473 £24,272 £3201
£10,000 £54,945 £48,544 £6401
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and Care Excellence (NICE). The Decision Support Unit 
(DSU) for NICE reported that there may be implications 
of the move from the 3-level to the 5-level version of the 
EQ-5D for the thresholds used to evaluate cost-efectiveness 
[15]. This introduces another issue to the ongoing debate 
over the threshold at which an intervention should be con-
sidered to be cost-efective in the UK, currently argued 
to be anywhere between £12,000 and £30,000 per QALY 
gained [21–24]. To ensure that an intervention has the same 
likelihood of being classiied as cost-efective, regardless 
of which approach is used to generate utility values from 
the EQ-5D-5L, it may be appropriate to deine a diferent 
threshold for each approach. This may be less of an issue 
when comparing the two methods of utility estimation for 
the 5-level version because the diference in the distribution 
of values for 5L-SP versus crosswalk is smaller than that for 
5L-SP versus 3L-TTO [16].
In conclusion, the differences in EQ-5D-5L-derived 
utility values estimated using the crosswalk and 5L-SP 
approaches appear to be broadly similar among samples with 
mental health conditions and other health conditions. There 
are implications of utility estimation approach for decision-
making and comparing and combining data from diferent 
studies. The implications are likely to be greatest for people 
reporting extreme anxiety/depression and evaluations over 
long time horizons. Updated guidance from NICE and other 
bodies for how this should be reported and implications han-
dled in terms of health technology assessment is needed.
Funding  This study received no direct funding for secondary analysis 
of trial data. The original trials were funded by NIHR Collaboration 
for Leadership in Applied Health Research and Care for Greater Man-
chester (COINCIDE), NIHR programme Grant (Grant No. RP-PG-
1210-12007) (EQUIP), and NIHR HTA Project Grant (Grant No. 
HTA-10/101/02) (FOCUS). The views expressed in this article are 
those of the authors and not necessarily those of the NIHR, NHS, or 
the Department of Health. 
Compliance with ethical standards 
Conflict of interest All authors declare that they have no conlicts of 
interest.
Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards. 
For the COINCIDE trial—the trial was approved by the National 
Research Ethics Service Committee North West-Preston (NRES/11/
NW/0742); research governance approvals were granted by participat-
ing primary care trusts. For the EQUIP trial—the trial was approved by 
the National Research Ethics Service Committee North West-Lancaster 
(NRES/14/NW/0297). For the FOCUS trial—the trial was approved 
by the National Research Ethics Committee North West-Lancaster 
(NRES/12/NW/0520).
Informed consent Informed consent was obtained from all individual 
participants included in the studies.
Open Access This article is distributed under the terms of the Creative 
Commons Attribution 4.0 International License (http://creativecom-
mons.org/licenses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Appleby, L., Asherson, P., Aznar, C., Bebbington, P., Bridges, 
S., Brugha, T., … Wessely, S. (n.d.). Mental health and wellbe-
ing in England. Adult Psychiatric Morbidity Survey 2014.
 2. Mental Health Foundation. (2015). Fundamental Facts About 
Mental Health. Retrieved from https://www.mentalhealth.org.
uk/sites/default/iles/fundamental-facts-15.pdf.
 3. Saarni, S. I., Suvisaari, J., Sintonen, H., Pirkola, S., Koskinen, 
S., Aromaa, A., & Lönnqvist, J. (2007). Impact of psychiatric 
disorders on health-related quality of life: General population 
survey. British Journal of Psychiatry. https://doi.org/10.1192/
bjp.bp.106.025106.
 4. Roberts, J., Lenton, P., Keetharuth, A. D., & Brazier, J. (2014). 
Quality of life impact of mental health conditions in England: 
Results from the adult psychiatric morbidity surveys. Health 
and Quality of Life Outcomes, 12(6). Retrieved from https://
hqlo.biomedcentral.com/articles/10.1186/1477-7525-12-6
 5. Connell, J., Brazier, J., O’Cathain, A., Lloyd-Jones, M., 
& Paisley, S. (2012). Quality of life of people with men-
tal health problems: A synthesis of qualitative research. 
Health and Quality of Life Outcomes, 10(1), 138. https://doi.
org/10.1186/1477-7525-10-138.
 6. The EuroQoL Group. (1990). EuroQol-a new facility for the 
measurement of health-related quality of life. Health Policy, 
16(3), 199–208.
 7. The EuroQoL Group. (n.d.). EQ-5D Products. Retrieved from 
http://www.euroqol.org/eq-5d-products.html.
 8. Dolan, P., Gudex, C., Kind, P., & Williams, A. (1996). The 
time trade-of method: Results from a general population study. 
Health Economics, 5(2), 141–154.
 9. National Institute of Health and Care Excellence (NICE). 
(2013). Guide to the methods of technology appraisal. National 
Institute for Clinical Excellence.
 10. Brazier, J. (2010). Is the EQ-5D it for purpose in mental health 
? The British Journal of Psychiatry, 197(5), 348–349. https://
doi.org/10.1192/bjp.bp.110.082453.
 11. Mulhern, B., Mukuria, C., Barkham, M., Knapp, M., Byford, S., 
Soeteman, D., & Brazier, J. (2014). Using generic preference-
based measures in mental health: Psychometric validity of the 
EQ-5D and SF-6D. The British Journal of Psychiatry, 205(3), 
236–243. https://doi.org/10.1192/bjp.bp.112.122283.
 12. van Hout, B., Janssen, M. F., Feng, Y.-S., Kohlmann, T., 
Busschbach, J., Golicki, D., … Pickard, A. S. (2012). Interim 
scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-
5D-3L value sets. Value in Health, 15(5), 708–715. https://doi.
org/10.1016/j.jval.2012.02.008.
 13. Oppe, M., Devlin, N. J., Van Hout, B., Krabbe, P. F. M., & De 
Charro, F. (2014). A program of methodological research to 
arrive at the new international eq-5d-5 l valuation protocol. 
Value in Health, 17(4), 445–453. https://doi.org/10.1016/j.
jval.2014.04.002.
 14. Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, 
B. (2017). Valuing health-related quality of life: An EQ-
5D-5L value set for England. Health Economics. https://doi.
org/10.1002/hec.3564.
724 Quality of Life Research (2018) 27:717–724
1 3
 15. Wailoo, A., Alava, M. H., Grimm, S., Pudney, S., Sadique, Z., 
Meads, D., … Irvine, L. (2017). Comparing the EQ-5D-3L and 
5L Versions. What are the Implications for Cost Efectiveness 
Estimates?, (March), 1–58. Retrieved from http://www.nicedsu.
org.uk/DSU_3Lto5LFINAL.pdf.
 16. Mulhern, B., Feng, Y., Shah, K., van Hout, B., Janssen, B., 
Herdman, M., & Devlin, N. (2017). Comparing the UK EQ-
5D-3L and the English EQ-5D-5L value sets. The Oice of 
Health Economics - Research Paper.
 17. Coventry, P. A., Lovell, K., Dickens, C., Bower, P., Chew-Gra-
ham, C., Cherrington, A., … Roughley, K. (2012). Collaborative 
interventions for circulation and depression (COINCIDE): Study 
protocol for a cluster randomized controlled trial of collaborative 
care for depression in people with diabetes and/or coronary heart 
disease. Trials, 13(1), 139.
 18. Bower, P., Roberts, C., O’Leary, N., Callaghan, P., Bee, P., Fraser, 
C., … Lovell, K. (2015). A cluster randomised controlled trial 
and process evaluation of a training programme for mental health 
professionals to enhance user involvement in care planning in 
service users with severe mental health issues (EQUIP): Study 
protocol for a randomised controlled trial. Trials, 16, 348. https://
doi.org/10.1186/s13063-015-0896-6.
 19. Pyle, M., Norrie, J., Schwannauer, M., Kingdon, D., Gumley, A., 
Turkington, D., … Morrison, A. P. (2016). Design and protocol 
for the focusing on clozapine unresponsive symptoms (FOCUS) 
trial: A randomised controlled trial. BMC Psychiatry, 16, 280. 
https://doi.org/10.1186/s12888-016-0983-6.
 20. Ramos-Goñi, J. M., & Ramallo-Fariña, Y. (2016). Equation 5dds: 
A command to analyze the descriptive system of EQ-5D quality 
of life instrument. The Stata Journal, 16(3), 691–701.
 21. Oice of Health Economics. (2015). OHE Occasional Paper 
Critiques the Claxton et al. £13,000 per QALY Estimate. Oice 
of Health Economics. Retrieved from https://www.ohe.org/
news/ohe-occasional-paper-critiques-claxton-et-al-£13000-qaly-
estimate.
 22. McCabe, C., Claxton, K., & Culyer, A. J. (2008). The NICE cost-
efectiveness threshold. Pharmacoeconomics, 26(9), 733–744.
 23. National Institute of Health and Care Excellence (NICE). (2015). 
Carrying NICE Over the Threshold. National Institute for Health 
and Care Excellence. Retrieved from http://www.nice.org.uk/
news/blog/carrying-nice-over-the-threshold.
 24. Claxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., 
Hinde, S., … Sculpher, M. (2015). Methods for the estimation 
of the National Institute for Health and Care Excellence cost-
efectiveness threshold. Health Technology Assessment, 19, 1
